Gaize is a technology company.
Gaize has raised $1.0M across 1 funding round.
Gaize has raised $1.0M in total across 1 funding round.
Gaize has raised $1.0M in total across 1 funding round.
Gaize's investors include Acequia Capital, Album VC, Andreessen Horowitz, Adeyemi Ajao, Craft Ventures, DCM, Hanaco Ventures, iNovia Capital, Khosla Ventures, Lightspeed Venture Partners, Long Journey Ventures, Startup Ignition Ventures.
# High-Level Overview
Gaize is an impairment detection technology company that automates drug and alcohol screening through eye-tracking tests.[1][3] Founded in 2021 and based in Missoula, Montana, the company addresses a critical gap in workplace and roadway safety: the lack of rapid, objective screening tools for active drug impairment as cannabis legalization accelerates across the United States and globally.[1][2]
The company serves safety-sensitive industries including construction, manufacturing, and law enforcement.[2] Gaize's core product performs automated ocular examinations—measuring micro-movements of the eye—to detect impairment from cannabis, alcohol, opioids, stimulants, depressants, and some psychedelics in approximately 6 minutes.[3][4] This approach is substantially cheaper and faster than traditional lab-based chemical testing, positioning Gaize as a practical alternative for employers managing fit-for-duty decisions and workplace safety programs.[3][4]
# Origin Story
Gaize was founded in 2021 by Ken Fichtler (CEO) and Rob Kaufmann (CTO), alongside a small team including Dan Zell (Account Executive), Reagan Werner (Business Development), and Apurva Raje (Research Coordinator).[1][2] The company emerged from a straightforward observation: while cannabis legalization was inevitable, no rapid, portable screening test existed to detect active impairment in drivers or workers.[1]
Rather than inventing from scratch, the founders built upon 45 years of proven law enforcement science—Drug Recognition Expert (DRE) eye examinations that have been validated through thousands of court cases and dozens of clinical trials.[3] The innovation was automating these manual tests using artificial intelligence and machine learning, eliminating human error and bias while making the technology accessible to businesses for the first time.[1][3][4] This foundation in established science, combined with modern AI, gave Gaize credibility from inception.
# Core Differentiators
# Role in the Broader Tech Landscape
Gaize sits at the intersection of AI-driven automation and regulatory necessity. As cannabis legalization spreads, employers and law enforcement face an urgent compliance challenge: how to objectively measure impairment without reliable tools. Gaize's timing is optimal—the company rides the wave of both cannabis legalization and the broader workplace safety technology trend, where AI is automating subjective human judgments.
The company also represents a shift in drug testing philosophy: from detecting substance presence (which doesn't indicate impairment) to detecting active impairment (which does). This distinction matters legally and practically, especially as cannabis becomes normalized and employers need defensible, objective safety decisions.
Gaize's inclusion in AI expert collections reflects its positioning as an artificial intelligence application rather than merely a hardware device—the machine learning algorithms that detect subtle ocular patterns are central to its value proposition.[2] The company influences the broader occupational health and safety ecosystem by demonstrating how legacy law enforcement science can be modernized and democratized through technology.
# Quick Take & Future Outlook
Gaize has solved a genuine problem at a critical inflection point. The company has raised $1.23M to date and is actively hiring, suggesting expansion plans.[2] Its near-term trajectory likely involves deepening penetration in construction and manufacturing while exploring adjacent markets in law enforcement and transportation.
The broader question is whether Gaize becomes the standard for impairment screening as cannabis legalization accelerates, or whether it faces competition from alternative detection methods. The company's defensibility rests on its scientific foundation and first-mover advantage in automation—but regulatory acceptance will ultimately determine scale. If courts and regulatory bodies embrace Gaize's ocular testing as legally defensible evidence of impairment, the company could capture significant market share in a rapidly expanding safety-tech sector. The next phase will likely involve expanding clinical validation, navigating biometric privacy regulations, and scaling distribution beyond construction into transportation and broader workplace safety.
Gaize has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $1.0M Seed | Acequia Capital, Album VC, Andreessen Horowitz, Adeyemi Ajao, Craft Ventures, DCM, Hanaco Ventures, iNovia Capital, Khosla Ventures, Lightspeed Venture Partners, Long Journey Ventures, Startup Ignition Ventures, Tet Ventures, Eric Wu, JD Ross, Justin Timberlake, Michael Stoppelman, Tony Xu, Wayne Ting |